Polycystic ovary syndrome (PCOS) is a common hormonal disorder in women, and is caused by a combination of environmental and genetic factors in which the ovaries accumulate tiny cysts resulting into the enlargement of ovaries with cysts on the outer edges. Some effects of PCOS includes irregular or absent menstrual cycle, excess androgen, excess hair growth, weight gain, and depression. Currently, there is no cure, but the symptoms of PCOS can be minimized with proper treatment and medication.
Weight gain and insulin resistance are two major symptoms associated with PCOS. In addition, increasing prevalence of diabetes and obesity in women are other factors contributing to growth of the global polycystic ovarian syndrome treatment market. Moreover, rising awareness about the disorder globally, coupled with several government and non-profit organizations providing education and support services for women, is anticipated to further drive growth of the global polycystic ovarian syndrome treatment market over the forecast period.
A major factor restraining growth of the global polycystic ovarian syndrome treatment market is easy availability of generic and off label drugs in the market.
However, technological advancements and innovations focusing on development of specific drugs or treatments is expected to create new opportunities for major players in the global polycystic ovarian syndrome treatment market over the forecast period.
The global polycystic ovarian syndrome treatment market report has been segmented on the basis of drug type, surgery type, and region. On the basis of region, the global polycystic ovarian syndrome treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Do Inquiry About Report Here: https://marketresearch.biz/report/polycystic-ovarian-syndrome-treatment-market/#inquiry
North America market dominates the global polycystic ovarian syndrome treatment market in terms of revenue contribution as compared to that of markets in other regions. This is attributed to well-developed healthcare infrastructure and availability of skilled medical personnel, presence of leading manufacturers, and large PCOS patient pool in countries in the region. Europe accounts for second-largest revenue share contribution to the global polycystic ovarian syndrome treatment market, followed by markets in Latin America, Asia Pacific, and Middle East & Africa respectively. The market in Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years, owing to increasing patients pool and increasing awareness regarding the disorder in some major countries in the region.
Some prominent players in the global polycystic ovarian syndrome treatment market are Sanofi S.A., Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., AstraZeneca Plc., Abbott Laboratories, Bayer AG, Teva Pharmaceutical Industries Ltd., and Ferring Pharmaceuticals.